- Flu Challenge Studies at NIH
- Politics and Plagues
- OPERATION WHITECOAT
- You may hold the cure for the next epidemic
- National Security Implications of CRISPR-CAS9
- If Not Me, Then Who?
- JUMP START: ACCELERATING GOVERNMENT RESPONSE TO A NATIONAL BIOLOGICAL CRISIS
- The Reemergent 1977 H1N1 Strain and the Gain-of-Function Debate
- Ebola 2014: Pandemic Preparedness Lessons Learned
- Mitigating the Risks of Synthetic Biology
- Tracking Down Smallpox Before It Kills Anew
- Penn and Teller on the Anti-Vaccine Idiots
- Interview about WMD Center’s Report Card on Bio-Response
- John Snow Society Pump Handle Lecture Series 2013
- LA Times Article on Richard Danzig
Daily Archives: October 8, 2012
Senior Director, Vaccines, Immunotherapeutics and Diagnostics Policy, Biotechnology Industry Organization
The timely availability of medical countermeasures—drugs, vaccines and other medical resources needed for a robust response—is a key component of US biosecurity. Ms. Arthur discusses the role of public-private partnerships in drug and vaccine development and production and broadly outlines the roles that Congress, the Administration, and the private sector play regarding US biodefense policy.
As a senior leader at the Biotechnology Industry Organization (BIO), Ms. Arthur has a unique and critical role at the interface between the resources and requirements of the US government and the research, development, manufacturing, and production capabilities of private industry.
Video produced by the Center for Biosecurity of UPMC